BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Misasi S, Martini G, Paoletti O, Calza S, Scovoli G, Marengoni A, Testa S, Caimi L, Marchina E. VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. Medicine (Baltimore) 2016;95:e5451. [PMID: 28033245 DOI: 10.1097/MD.0000000000005451] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Wu S, Chen X, Jin DY, Stafford DW, Pedersen LG, Tie JK. Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition. Blood 2018;132:647-57. [PMID: 29743176 DOI: 10.1182/blood-2018-01-830901] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
2 Liu J, Wang G, Qin L, Wu Y, Zou Y, Wang X, Wang Z, Wang Y, Zhang S, Zhang Y, Yin T. Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation. Cardiol Res Pract 2021;2021:9030005. [PMID: 34858664 DOI: 10.1155/2021/9030005] [Reference Citation Analysis]
3 Sanghera DK, Bejar C, Sapkota B, Wander GS, Ralhan S. Frequencies of poor metabolizer alleles of 12 pharmacogenomic actionable genes in Punjabi Sikhs of Indian Origin. Sci Rep 2018;8:15742. [PMID: 30356105 DOI: 10.1038/s41598-018-33981-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Jiang HH, Liu J, Wang YC, Ye HM, Li X, Zhou YX, Zhang W, Wang LS. The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin. Clin Appl Thromb Hemost 2018;24:640-6. [PMID: 28401802 DOI: 10.1177/1076029617703483] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Chen X, Jin DY, Stafford DW, Tie JK. Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu. Blood 2018;132:1974-84. [PMID: 30089628 DOI: 10.1182/blood-2018-05-846592] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
6 Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pac J Cancer Prev. 2018;19:2057-2070. [PMID: 30139042 DOI: 10.22034/apjcp.2018.19.8.2057] [Cited by in F6Publishing: 37] [Reference Citation Analysis]
7 Just KS, Dormann H, Schurig M, Böhme M, Fracowiak J, Steffens M, Scholl C, Seufferlein T, Gräff I, Schwab M, Stingl JC. Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?-Results from the ADRED Study. J Clin Med 2020;9:E1801. [PMID: 32527038 DOI: 10.3390/jcm9061801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Velizarova M, Hristova J, Svinarov D, Ivanova S, Jovinska S, Abedinov P. The impact of CYP2C9 and VKORC1 genetic polymorphisms in anticoagulant therapy management after cardiac surgery with extracorporeal circulation. PHAR 2021;68:269-73. [DOI: 10.3897/pharmacia.68.e63409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]